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Abstract
1. Background
Height, weight, and head circumference size are considered as one of the best indicators of infants’
general health. The abnormal growth may indicate the presence of a disease and/or a disorder
in apparently normal infants. The congenital hypothyroidism is one of the causes of growth
disorder in infants [1,2]. The congenital hypothyroidism was described as the lack of thyroid
hormone in birth time reported as one of the most common congenital endocrine disorders
as well as the most preventable causes of mental retardation and body growth disorders [3,4].
The incidence of congenital hypothyroidism was substantially increased in recent years with
ratio of 1:1400 to 1:2800 [4]. According to the studies performed in Iran, the incidence of the
aforementioned disorder was increased from the ratio of 1:1400 to 1:1900 being statistically higher
than the global average [5]. A meta-analysis study reported the incidence of newborns’ congenital
hypothyroidism with the ratio of 2:1000 in Iran [6].
The studies reported the prevalence of congenital hypothyroidism in different ranges in the
world being 7.14 in Nigeria to 14 per 1000 births in Japan [3,7]. The reports stated the higher
incidence of congenital hypothyroidism in Iran than other regions of the world before and after
applying the congenital hypothyroidism screening program [8,9]. in this regard, the national
studies have shown various incidence of congenital hypothyroidism in Iran with the ratio of
1:1000, 1:370, 1:1433, 1:400 and 1:1608 live births in Tehran, Isfahan, Shiraz, Kurdistan, and
Yazd, respectively [10–13]. Nowadays, the infants’ screening program application leads to the
early diagnosis of patients with various genetic and/or congenital diseases such as congenital
hypothyroidism and accordingly applying the suitable treatment with Levothyroxine alternative
dosage administration suppressing its adverse outcomes [14,15]. It has been accepted that
hypothyroidism in childhood, in spite of proper treatment, can disrupt growth in adulthood;
however, many studies have reported that children with congenital hypothyroidism are normal
from the onset of infancy by screening programs and treatment [16].
Some authors believe that several factors including age of treatment onset, utilized therapeutic
dosage, Thyroid Stimulating Hormone (TSH) normalization age and the severity of disorder
might affect the growth status of infants with congenital hypothyroidism. The effect of
aforementioned factors on growth pattern in infants with congenital hypothyroidism undergone
diagnosis through screening and early treatment in the onset of infancy was remained
controversial [16–18]. The studies demonstrated a normal pattern of body growth and height
in adulthood in infants with congenital hypothyroidism using the continuous treatment [17,18].
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Furthermore, the thyroid’s normal function plays an important role in brain development
prognosis. The patients that their T4 level becomes normal during 2 or more weeks after onset
of treatment significantly acquired a lower mark of brain development than whom reach to
normal level of T4 during 1 week after onset of treatment [19]. On the other hand, the several
authors reported a more severe pattern of brain development disorder in patients, undergone
late treatment and low dosage of Levothyroxine [19–21].
In a study performed to evaluate the various effects of early dosages of Levothyroxine on the
growth pattern of patients with congenital hypothyroidism, there wasn’t significant difference
between weight, height, and head circumference size of the patients groups, but the growth mean
of them was near to the normal growth mean basis on age. Although beginning of treatment with
high dosage of Levothyroxine immediately normalized the TSH serum level during a month and
leaded to Intelligence Quotient improvement in 4-year-old even in patients with severe congenital
hypothyroidism in the time of diagnosis, it couldn’t affect their growth [22].
The findings of several studies that have performed to evaluate the growth pattern of infants
with congenital hypothyroidism and related factors were various and controversial. Some studies
indicated the findings portraying delaying of growth in infants with congenital hypothyroidism,
but the early treatment leads to their normal growth pattern. Conversely, some studies reported
no significant difference in growth pattern between the infants with congenital hypothyroidism
and healthy ones [20,23–25].
Few studies performed to evaluate the therapeutic interventions effects and the related factors
on growth pattern of the infants with congenital hypothyroidism in Iran, to our knowledge,
and most of them assessed the patients’ mental disorders [11,26]. Therefore, given that the
physical problems associated with this disease are as important as the mental disabilities that
it is producing and affect the infants’ future life. Also, considering the high incidence of the
congenital hypothyroidism in Iran, the current study was conducted to evaluate the therapeutic
interventions’ effect on growth pattern of infants with congenital hypothyroidism in Yazd.
With the exception of Hashemipour’s study in Isfahan, such a study has not been conducted
in Iran and Yazd province so far. As regard very high prevalence of this disease in Iran, especially
in Yazd and also implementation of the neonatal screening program in this city for many years
which lead to early diagnosis and treatment interventions, therefore, this study was conducted
with the aim of evaluation of the therapeutic interventions’ effects on the growth pattern of infants
with congenital hypothyroidism in Yazd city. Consequently, timely and proper implementations
of screening programs and treatment interventions could be done by comparing the pattern of
physical growth of children in terms of the therapeutic factors taken by specialist physicians and
sending these results to doctors, healthcare policy officers and healthcare professionals.
2. Methods
(a) Design and implementation method of study
The current study was designed as a retrospective cohort and carried out on all of the
newborns with congenital hypothyroidism diagnosed through screening program and undergone
treatment. All of the newborns from 2007 to 2009 with hypothyroidism were diagnosed through
congenital hypothyroidism screening program and undergone treatment, were enrolled to the
study after meeting the inclusion and exclusion criteria; afterwards, the effect of related-indices
to the therapeutic interventions were assessed by physicians on growth pattern of height, weight,
and head circumference size of the infants with congenital hypothyroidism including the age
of treatment onset, the administered first dosage of Levothyroxine and normalization period of
serum T4 and TSH.
The inclusion criteria was all of the Yazd newborns diagnosed with congenital hypothyroidism
through screening program and referred to the healthcare center of Yazd to receive the healthcare
services. The exclusion criteria was all of the newborns of other regions diagnosed with congenital
hypothyroidism together with another disease including pre-mature newborns, intrauterine
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growth restriction (IUGR), subjects with genetic disorders such as Down syndrome as well as
infants with severe anomaly. Moreover, the lack of knowledge related to study’s main variables
was considered as exclusion criteria; for instance, undetermined age, and anthropometric
variables or apparent error in measurements.
(b) Screening program, diagnosis and treatment
The abnormal values based on screening function to diagnose congenital hypothyroidism were
included as TSH> 10 mU/L and T4< 6.5 µg/dl. The anthropometric indices were measured from
early infancy to 1 year of age every 3 months, from 1 to 2 year(s) of age every 6 months, and 2 to
over-2 years of age annually. In addition, height and weight as well as head circumference size
were measured to 5 and 2 years of age, respectively. Therefore, every infant were evaluated in 10
episodes for height and weight and 7 episodes for head circumference size after enrolling to the
study. According to the congenital hypothyroidism screening program of the infants in Iran, The
treatment begin was classified based on the newborn’s age as the following:
- Less than 28 days (favorable), from 28 to 40 days (acceptable), more than 41 days
(unfavorable)
- The normalization period of serum T4 and TSH level was categorized as the following based
on the aforementioned instruction.
The normalization period of T4 level was classified to two groups as ≤14 and >14 days
after initiating the treatment, respectively. Also, the normalization period of TSH level was
classified to two groups as ≤30 and >30 days after treatment begin, respectively. The infants with
congenital hypothyroidism were assigned to two groups as ≤25 and >25 µg/day based on the
first administered therapeutic dosage.
Generally, a total of 69 patients diagnosed with congenital hypothyroidism. Ultimately 55
patients were enrolled to the study after meeting the inclusion criteria. Then, the effectiveness
of therapeutic interventions on growth pattern was assessed.
(c) Data collection
In the present study, after coordination with an expert on congenital hypothyroidism and
obtaining the necessary permissions from the provincial health center and in coordination
with the doctor responsible for the treatment of affected children, an Excel file related to
the information of newborns diagnosed with hypothyroidism from 2006 - 2008. This file
included information about the factors of treatment interventions implemented for children with
hypothyroidism. Related variables were extracted from this file.
Furthermore, to collect data related to the anthropometric indices and physical growth pattern
(variables such as of height, weight, and head circumference) by referring to the form of
monitoring and care of newborns in health centers was executed by using data collection form.
(d) Data analysis
The collected data were analyzed using SPSS software version 22. In order to descriptive analyses
height, weight, head circumference size means were estimated based on gender, treatment age,
the first administered dosage of Levothyroxine and normalization period of serum T4 and TSH
level. In addition, independent sample t-test, repeated measures and ANOVA were utilized for
analytical analyses.
(e) Ethical consideration
- Obtaining informed consent from the doctor responsible for treatment interventions and parents
of patients.
- Data and information collected and published collectively.
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- The collected data have been kept confidential.
- Collected data have been used only to achieve the purpose of the study.
3. Results
The results of the current study were surveyed in two parts including descriptive and analytical
analyses. The descriptive results are presented in Table 1 showing 5 year-old growth, height,
weight, and head circumference size means of the infants with congenital hypothyroidism based
on gender, the administered dosage of Levothyroxine, age of treatment begin, normalization
period of T4 and TSH level. The 5 year-old growth mean of height, weight, and head
circumference in males was higher than that in the females. Also, the 5 year-old growth means of
height, weight, and head circumference in infants, undergone lower dosage of Levothyroxine
was greater than that in subjects, undergone higher dosage of Levothyroxine. The 5 year-old
growth means of height, weight, and head circumference in infants, undergone treatment in
early age was higher than that in the subjects, undergone treatment in late age. Furthermore,
the 5 year-old growth means of height, weight, and head circumference in infants with short-
term normalization time to adjust serum T4 and TSH was higher than that in the subjects with
long-term normalization time.
The trend of 5 year-old growth of height was assessed based on the administered dosage of
Levothyroxine (Figure 1 ) showing a significant trend of height growth in infants undergone
lower dosage of Levothyroxine being statistically insignificant through using Repeated Measure
(P= 0.37).
Figure 2 indicates the 5 year-old growth of height in infants with congenital hypothyroidism
based on age of treatment begin showing a significant height growth of infants undergone
treatment earlier than other subjects in all periods. A statistical significant difference was observed
between the height growth of infants, undergone treatment less than 28 days of diagnosis and the
subjects, undergone treatment more than 41 days of diagnosis (P< 0.001). Conversely, there was
no significant difference between the 5 year-old growth of height in infants, undergone treatment
from 28 to 40 days of diagnosis with other infants (P> 0.05).
Figure 3 indicates the 5 year-old growth of height in infants with congenital hypothyroidism
based on normalization period of serum TSH level showing a better height growth pattern of
infants with normalization period during 30 days as compared to the infants with normalization
period more than 30 days being statistically significant (P= 0.031).
Figure 4 indicates the 5 year-old growth of height in infants with congenital hypothyroidism
based on normalization period of serum T4 level showing a better height growth pattern of infants
with normalization period during 14 days as compared to the infants with normalization period
more than 14 days being statistically significant (P= 0.028).
Figure 1. Comparison of hight growthpattern according to dose of levothyroxine. Five year old growth pattern based
on dose of levothyroxine
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Figure 2. Comparison of hightgrowth pattern according to age of treatmeant begin. Pattern of 5-year-old growth of
childhood children based on the age of onset of treatment interventions.
Figure 3. Comparisonof hight growth pattern according to normalize time TSH level. 5-year growth pattern of
children’s height according to the normalization of serum TSH levels.
Figure 4. Comparison of hightgrowth pattern according to normalizetime of T4 level. 5-year growth pattern of
children’s height according to the normalization time of serum T4 level.
Comparison of weight growth of the infants with congenital hypothyroidism in different
periods was presented in Figures 5, 6, 7 and 8 based on the therapeutic indices from early infancy
to 60 months of age.
Figure 5 indicates weight growth of infants with congenital hypothyroidism based on the
administered dosage of Levothyroxine from early infancy to 60 months of age showing better
weight growth pattern of infants with lower dosage of Levothyroxine (≤ 25 µg/day) as compared
to the infants with higher dosage of Levothyroxine (>25 µg/day) being statistically insignificant
(P=0.33).
Figure 6 indicates weight growth of infants with congenital hypothyroidism based on the
age of treatment begin showing a better weight growth pattern of infants undergone treatment
immediately as compared to the infants undergone treatment lately.
The insignificant physical and weight growth was observed in infants, undergone medical
treatment lately (41 days after diagnosing). There was a significant difference between the weight
growth of infants undergone treatment after 41 days of diagnosis and the subjects undergone
Etemad et al. Biomedical Research and Therapy 2018, 5(4):2194-2207
Biomed. Res. Ther. 2018, 5(4):2194-2207 2200
2201
B
iom
ed.
R
es.
Ther.
2018,5(4):2194-2207
.............................................................
treatment before 41 days of diagnosis, but the height growth was not substantial in these infants
(P= 0.012).
Figure 7 indicates weight growth of infants with congenital hypothyroidism based on
the normalization period of serum TSH level showing a more significant weight growth of
infants with short-term normalization period (less than 30 days after applying the therapeutic
interventions) as compared to the subjects with long-term normalization period being statistically
significant (P= 0.041).
Figure 8 indicates weight growth of infants with congenital hypothyroidism based on the
normalization period of serum T4 level showing a more significant weight growth of infants with
short-term normalization period (less than 14 days after applying the therapeutic interventions)
as compared to the subjects with long-term normalization period (more than 14 days after
applying the therapeutic interventions) being statistically significant from early infancy to 24
months of age (P= 0.041), but there was no significant difference between the groups in terms
of weight growth trend after 24 months of age (P> 0.05).
Figure 5. Comparison of Wight growth pattern according to dose of levothyroxine. The pattern of growth in children
from birth to 60 months of age is based on the dose of treatment.
Figure 6. Comparison of wight growth pattern according to age oftreatmeant begin. The growth pattern of the child’s
weight by the age of initiation of treatment.
Comparison of head circumference growth of the infants with congenital hypothyroidism in
different periods was presented in Figures 9, 10, 11 and 12 based on the therapeutic indices from
early infancy to 60 months of age. A remarkable similarity in head circumference development
was observed between the infants. Therefore, there was no statistical significant difference
between the head circumference growth in infants (P> 0.05).
4. Discussion
The current study was designed as a longitudinal retrospective cohort performed on a total of
55 infants with congenital hypothyroidism diagnosed through the screening program undergone
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Figure 7. Comparison of Wightgrowth pattern according tonormalization time TSH level. The pattern of weight gain
of children in terms of the normalization time of the TSH level serum.
Figure 8. Comparison of Wightgrowth pattern according tonormalization time T4 level. Comparison of children’s
weight growth pattern with duration of normalization of serum T4 level.
Figure 9. Comparison of Head Circumference growth pattern according to dose of levothyroxine. Comparison of
the growth pattern of the patient’s child at different time points from birth to 60 months of age.
Figure 10. Comparison of Head Circumference growth pattern according to age ot treatmeant begin. Comparison
of the growth pattern of the patient’s child at different time points from birth to 60 months of age.
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Figure 11. Comparison of Head Circumference growth pattern according to normalization time T4 level.
Comparison of the growth pattern of the patient’s child at different time points from birth to 60 months of age.
Figure 12. Comparison of Head Circumference growth pattern according to normalization time TSH level.
Comparison of the growth pattern of the patient’s child at different time points from birth to 60 months of age.
treatment afterwards. They were evaluated in terms of 5 year-old growth of height, weight, and
head circumference based on the therapeutic interventions indices including age of treatment
begin, the administered dosage of Levothyroxine and normalization time of T4 and TSH level.
The results of the current study showed a significant increase in height, weight, and head
circumference in infants from early infancy to 60 months of age as well as an ascending trend
of the aforementioned variables.
Too many challenges were proposed for administering the necessary dosage of Levothyroxine
as well as the normal level of TSH in recent years [27]. The effect of medication dosage and
time of alternative treatment onset on newborns with congenital hypothyroidism has been
always controversial. The European and American Guidelines have suggested the high dosage
of Levothyroxine for treatment begin which has been controversial [7,28]. Also, according
to a systematic review, there was little evidence to represent the effects of starting dosage
of Levothyroxine on the growth of newborns with congenital hypothyroidism [29]. The
starting dosage of Levothyroxine was suggested as 10-15 µg/kg based on the severity of
hypothyroidism [30].
The trend of 5 year-old growth of height was assessed in the current study based on
the administered dosage of Levothyroxine and infants who had received lower dosage of
Levothyroxine (25 µg/day>) had better trend of height growth.
The trend of weight growth of infants with congenital hypothyroidism was assessed based
on the administered dosage of Levothyroxine from early infancy to 60 months of age showing a
higher weight growth of infants with lower dosage of Levothyroxine (≤ 25 µg/day) as compared
to the infants with higher dosage of Levothyroxine (>25 µg/day).
The newborns with congenital hypothyroidism receiving higher dosage of 9.5 µg/kg/day
of Levothyroxine before 13 days of diagnosis reached to growth and development comparable
to reference population in the study of Jacoba et al. [20]. Moreover, several studies reported
significant growth improvement in infants with severe congenital hypothyroidism undergone
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administration of higher starting dosage of Levothyroxine as 10-15 µg/kg/day as well as early
treatment [31–33]. The results of the current study showed a better physical and weight growth
in infants, undergone medical treatment immediately after diagnosis (less than 28 days) as
compared to the infants received treatment lately (41 days after diagnosing). Some studies
demonstrated a significant correlation between the weight growth with age of treatment onset
and therapeutic starting dose while a significant correlation was observed between the head
circumference size with therapeutic starting dose [34]. Grant (1994) and Hashemipour et al. (2015)
reported that the growth status of the infants with congenital hypothyroidism depends on the
several factors such as therapeutic dose of medication [16,34].
Furthermore, a study reported the normal physical growth of the infants in first 3 years of
life, immediately diagnosed and undergone treatment [35]. Nevertheless, some studies reported
the latency in height growth improvement of the infants depends on LT4 dosage and, ages of
treatment begin [1,36,37]. The height and weight of the patients with the age of treatment begin
less than 30 days were significantly higher in some studies which are compatible with the results
of the current study [34,38,39]. Moschini et al. (1986) reported the normal height growth in 6 years
old with the age of treatment begin during 33 days after birth [39].
There was no significant correlation between the final height of the patients, age of treatment
begin, and administered dosage of Levothyroxine in the studies carried out in Japan and
Italy [14,40]. In the study conducted in Italy on a total of 215 patients during 2 decades, in spite of
using screening programs and treatment, the height growth of patients was increased. However,
this increase has not improved since the last 20 years and also ultimate height is not affected by
the birth date, the patient’s age at the time of diagnosis, the initial dose of levothyroxine [14]. The
significant effect of the starting dosage of Levothyroxine was reported on the height and weight
distribution of the patients with congenital hypothyroidism in a study performed in Isfahan.
The study indicated higher height and weight growth in patients received the starting dosage
of Levothyroxine as ≥33.33 µg/day as compared to the subjects received lower starting dosage.
Moreover, there was a significant correlation between the longitudinal growth of height and
weight with the age of treatment begin and starting dosage of Levothyroxine in all percentiles [41].
The results of the current study showed the similarity of head circumference growth trend in
different periods of time from early infancy to 60 months of age being statistically insignificant
in the therapeutic interventions’ indices. Conversely, a study reported the significant correlation
between height and weight growths with starting dose as compared to the insignificant
correlation between head circumference growth with starting dose [13].
A study carried out in Isfahan showed a significant correlation between head circumference
growth with starting dosage of Levothyroxine as compared to the insignificant correlation with
the age of treatment begin. The head circumference growth in patients with starting dosage of
Levothyroxine≥33.33 µg/day was better in patients with starting dosage <33.33 µg/day [41]. The
heterogeneity effect of normalization age of T4 was reported on head circumference as compared
to the significant effect of normalization age of TSH on physical growth of patients with congenital
hypothyroidism [16,34].
5. Conclusions
The significant effect of therapeutic interventions was reported on height, weight, and head
circumference growths of patients with congenital hypothyroidism. The age of treatment begin
less than 30 days plays an important role in promoting of height and weight growth of patients
with congenital hypothyroidism. The better trend of height and weight growth was reported in
infants with normalization time of TSH during 30 days after diagnosing. The substantial trend of
weight and height growths might be demonstrated in infants with normalization age of T4 less
than 14 days. The pattern of head circumference growth would be increased equally and similarly
in patients after treatment.
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Suggestions
It is suggested to refer the infants with congenital hypothyroidism to healthcare center so as to
receive medical treatment immediately after diagnosing of the disease; then, the treatment must
not be stopped after normalizing of serum T4 and TSH levels, the laboratory tests should be
repeated afterwards, and received a significant treatment.
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